Champions Oncology Drives Revenue Growth and Margin Gains Through Radiopharma and Data Innovation

Earnings Call Insights: Champions Oncology (CSBR) Q1 2026

Management View

The CEO, Rob Brainin, highlighted that fiscal 2025 is a critical year for the company as it recovers from a challenging 2024, achieving record revenue and profitability. He emphasized his commitment to building on the strong foundation, refining strategic execution, and positioning the company for long-term growth. Brainin noted the continued focus on value opportunities in Corellia and the data business, along with the expansion of the core TOS platform.

He mentioned that the company delivered $14 million in revenue, recovering from temporary softness in the previous quarter. Growth was driven by the TOS business, with meaningful contributions from the emerging data platform. Customer cancellations have decreased, and the conversion of bookings to revenue has increased. Additionally, growing relationships with large pharmaceutical companies are creating opportunities for larger, more durable bookings.

Brainin also highlighted the radiopharmaceutical services platform, stating that with a new radioactive materials license, radiochemistry infrastructure, and over 30 screened PDX models, the company can now deliver fully integrated workflows from biodistribution to efficacy testing on clinically relevant tumor models.

On the data platform, Brainin noted that the company has generated data sales for three consecutive quarters and expressed confidence in the long-term opportunity as AI and machine learning become increasingly central to drug discovery. Regarding Corellia, he described the data as compelling and reiterated confidence in its future value.

Financial Results

David Miller, the CFO, stated that revenue for Q1 was $14 million, essentially flat with the first quarter of last year but representing a solid rebound from the $12.4 million reported in Q4. On a GAAP basis, the company recorded a loss from operations of $0.5 million compared to income from operations of $1.3 million in the same quarter last year.

Miller explained that the cost of sales for the quarter was $8 million compared to $7 million last year, resulting in a gross margin of 43% versus 50% in Q1 of last year. The margin decline was primarily due to an increase in outsourced lab service costs for radio labeling work. As the company brings this work in-house, it anticipates gross margin expansion.

The company ended Q1 with $10.3 million in cash, up $0.5 million from year-end. It remains debt-free, with positive operating cash flow of $0.6 million supported by receivables conversion and normal working capital activity.

Outlook

Miller stated that the company expects sequential revenue growth, continued profitability on an adjusted EBITDA basis, and margin expansion as radio labeling work shifts in-house. Management expects to remain roughly cash neutral in Q2, with cash growth anticipated in the second half of fiscal 2026 as revenues increase and margins expand.

Management maintained confidence in both near-term trajectory and long-term outlook, citing the strength of its balance sheet and ongoing strategic investments.

Q&A Highlights

During the Q&A session, George Marema from Pareto Ventures asked about changes in the strategy for the data licensing business. Brainin responded that there are no changes, emphasizing that it's still early. He mentioned some early wins and potential in the space.

Marema also questioned the size of the data opportunity relative to the traditional business. Brainin replied that it's still early and premature to predict the exact size and success of this opportunity. He acknowledged the potential.

Another question regarding deal structures for Corellia led Brainin to state that the company is actively involved in raising funds to support the wholly owned subsidiary, seeking external partners and funding.

Tollef Kohrman from Craig-Hallum sought commentary on the investment landscape and customer behavior. Brainin noted that the environment remains tough but cautiously optimistic about improving market conditions and easing budget constraints.

Kohrman asked about the timing of stabilization and growth. Miller answered that the company feels like this is potentially the low point for the fiscal year in terms of revenue, anticipating expansion over the coming quarters.

An unidentified analyst asked for Q2 revenue color. Miller stated that he anticipates revenue will increase on a quarterly basis but refrained from providing exact numbers or percentages at this time.

Sentiment Analysis

Analysts maintained a cautiously optimistic tone, seeking clarity on the data business, deal structure, and near-term revenue trajectory. Management's tone was confident and pragmatic during prepared remarks, using phrases like "I'm confident in our ability to execute and deliver lasting value for our shareholders." However, during Q&A, the tone was slightly more guarded, especially regarding the timing and size of new opportunities.

Compared to the previous quarter, management remained steady in its optimism, with a new CEO adding an emphasis on foundational strength and strategic continuity. Analysts' sentiment held steady quarter-over-quarter, with ongoing focus on the macro environment, data monetization, and operational execution.

Quarter-over-Quarter Comparison

Q1 revenue rebounded to $14 million from $12.4 million in Q4, reflecting stabilization after prior softness. Gross margin declined to 43% from 50% in the year-ago quarter, attributed to outsourced radiolabeling costs, but management expects improvement with in-house capabilities.

Operating expenses increased by $1 million year-over-year, with intentional investments in R&D and sales and marketing for the data business. Management guidance language remained focused on sequential revenue growth and margin expansion, consistent with the previous quarter.

Analysts continued to press for clarity on the data business and near-term revenue trends, mirroring prior calls. The new CEO's tone emphasized continuity and a forward-looking strategy, while the CFO reiterated confidence in both near-term and long-term outlooks.

Risks and Concerns

Management acknowledged the still-challenging macro environment, especially regarding biotech funding and R&D budgets. Brainin cited reduced customer cancellations and improved bookings to revenue conversion, but also noted the ongoing need for execution in the data business and external funding for Corellia.

Miller highlighted that margin pressure was primarily due to an increase in outsourced lab service costs for radio labeling work, with mitigation through internalization of these processes. Analysts raised concerns about the predictability and scale of the data business, as well as the timing of revenue growth in the coming quarters.

Final Takeaway

Champions Oncology's Q1 2026 results signaled a return to revenue growth and operational stability following a soft prior quarter, supported by strength in the core TOS platform and emerging contributions from the data and radiopharma businesses. Management, under new CEO Rob Brainin, reiterated confidence in sequential revenue growth and margin expansion, with ongoing investments in the high-margin data platform and the transition of radiolabeling capabilities in-house expected to support profitability. The company remains debt-free with a strong cash position and maintains a disciplined approach to cost management and strategic execution as it targets further growth and value creation for shareholders.